Cargando…

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series

The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannantuono, Giovanni Maria, Riondino, Silvia, Sganga, Stefano, Rosenfeld, Roberto, Guerriero, Simona, Carlucci, Manuela, Capotondi, Barbara, Torino, Francesco, Roselli, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/
https://www.ncbi.nlm.nih.gov/pubmed/36579526
http://dx.doi.org/10.3390/jpm12111819
_version_ 1784837954020048896
author Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Rosenfeld, Roberto
Guerriero, Simona
Carlucci, Manuela
Capotondi, Barbara
Torino, Francesco
Roselli, Mario
author_facet Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Rosenfeld, Roberto
Guerriero, Simona
Carlucci, Manuela
Capotondi, Barbara
Torino, Francesco
Roselli, Mario
author_sort Iannantuono, Giovanni Maria
collection PubMed
description The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarcomas, lung, and salivary gland cancer. However, as next-generation sequencing assays are increasingly available in the clinical setting, health care professionals may be able to detect NTRK gene fusions in patients affected by tumor types under or not represented in the clinical trials. To this aim, we systematically reviewed MEDLINE from its inception to 31 August 2022 for case reports and case series on patients with NTRK gene fusion-positive tumors treated with TRK inhibitors. A virtual cohort of 43 patients was created, excluding those enrolled in the above-mentioned clinical trials. Although our results align with those existing in the literature, various cases of central nervous system tumors were registered in our cohort, confirming the benefit of these agents in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by tumor types under or not represented in the clinical trials.
format Online
Article
Text
id pubmed-9695027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96950272022-11-26 NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Rosenfeld, Roberto Guerriero, Simona Carlucci, Manuela Capotondi, Barbara Torino, Francesco Roselli, Mario J Pers Med Review The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarcomas, lung, and salivary gland cancer. However, as next-generation sequencing assays are increasingly available in the clinical setting, health care professionals may be able to detect NTRK gene fusions in patients affected by tumor types under or not represented in the clinical trials. To this aim, we systematically reviewed MEDLINE from its inception to 31 August 2022 for case reports and case series on patients with NTRK gene fusion-positive tumors treated with TRK inhibitors. A virtual cohort of 43 patients was created, excluding those enrolled in the above-mentioned clinical trials. Although our results align with those existing in the literature, various cases of central nervous system tumors were registered in our cohort, confirming the benefit of these agents in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by tumor types under or not represented in the clinical trials. MDPI 2022-11-02 /pmc/articles/PMC9695027/ /pubmed/36579526 http://dx.doi.org/10.3390/jpm12111819 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Rosenfeld, Roberto
Guerriero, Simona
Carlucci, Manuela
Capotondi, Barbara
Torino, Francesco
Roselli, Mario
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title_full NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title_fullStr NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title_full_unstemmed NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title_short NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
title_sort ntrk gene fusions in solid tumors and trk inhibitors: a systematic review of case reports and case series
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/
https://www.ncbi.nlm.nih.gov/pubmed/36579526
http://dx.doi.org/10.3390/jpm12111819
work_keys_str_mv AT iannantuonogiovannimaria ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT riondinosilvia ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT sgangastefano ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT rosenfeldroberto ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT guerrierosimona ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT carluccimanuela ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT capotondibarbara ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT torinofrancesco ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries
AT rosellimario ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries